{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cognition Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"CGTX"},"Address":{"label":"Address","value":"2500 WESTCHESTER AVENUE, PURCHASE, New York, 10577, United States"},"Phone":{"label":"Phone","value":"+1 412 481-2210"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex."},"CompanyUrl":{"label":"Company Url","value":"https://www.cogrx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Anthony O. Caggiano","title":"Chief Medical Officer, Head-Research & Development"},{"name":"Lisa R. Ricciardi","title":"President, Chief Executive Officer & Director"},{"name":"Mary Hamby","title":"Vice President-Research"},{"name":"Paul J. Tiseo","title":"Vice President-Clinical Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}